Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:26:58.550Z.
Calculation as of: 2026-10-06T21:26:58.550Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80f889fb03c5e90f23e6dbb960addb407f240d79d9565bd54dedfb6815f2f0ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$4.31B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.48B
EV/EBIT Ratio
9.20x
TTM Avg
11.90x
3Y Avg
40.42x
5Y Avg
37.42x
Market Cap
$4.60B
EV/EBIT Ratio
96.81x
TTM Avg
157.20x
3Y Avg
157.20x
5Y Avg
157.20x
Market Cap
$4.64B
EV/EBIT Ratio
16.90x
TTM Avg
15.96x
3Y Avg
18.18x
5Y Avg
22.57x
Market Cap
$4.70B
EV/EBIT Ratio
59.61x
TTM Avg
192.46x
3Y Avg
192.46x
5Y Avg
192.46x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.37B | N/A | N/A | N/A | N/A |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.31B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.48B | 9.20x | 11.90x | 40.42x | 37.42x |
| BillionToOne, Inc. (BLLN)vs › | $4.60B | 96.81x | 157.20x | 157.20x | 157.20x |
| LivaNova PLC (LIVN)vs › | $4.12B | 19.93x | 18.41x | 129.51x | 140.01x |
| Relay Therapeutics, Inc. (RLAY)vs › | $4.11B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.64B | 16.90x | 15.96x | 18.18x | 22.57x |
| LifeStance Health Group, Inc. (LFST)vs › | $4.70B | 59.61x | 192.46x | 192.46x | 192.46x |
| AbCellera Biologics Inc. (ABCL)vs › | $4.02B | N/A | 9.12x | 14.02x | 14.02x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
